In addition, the TAR vector targets more Cy5.5-MAL to the tumor site, thereby reducing the distribution of Cy5.5-MAL in normal tissues, which may facilitate the reduction of systemic toxicity in the future delivery of drugs. Here, MAL is linked to neoplasm.